معرفی
Dr. Fabio Simoes is an Assistant Professor in Cancer Research within the Clinical and Experimental Medicine department at Brighton and Sussex Medical School (BSMS), part of the University of Sussex. With over a decade of experience in disease modeling and molecular biology, he leads a research laboratory focused on acute myeloid leukaemia (AML) and the bone marrow microenvironment.
Dr. Simoes completed his PhD at BSMS in 2017, following earlier degrees including an MSc in Neuroscience from King's College London and a BSc in Biomedical Sciences from Queen Mary University of London. His research journey began with motor neuron disease studies, progressed through osteoarthritis research, and has now focused on hematological malignancies.
His current research examines how AML cells remodel the bone marrow microenvironment to promote disease progression and therapy resistance. By employing in vitro co-culture systems, RNA sequencing, and translational in vivo models, his work aims to identify novel therapeutic targets such as CD44 and Focal Adhesion Kinase to overcome cell adhesion-mediated drug resistance. Analysis of his recent publications reveals a strong focus on tumor microenvironment interactions, computational modeling of blood cancers, and translational approaches to improve treatment outcomes.
Dr. Simoes currently holds an active research grant from the SUSSEX CANCER FUND FOR TREATMENT AND RESEARCH (2024-2028) focused on characterizing and targeting chemo-resistant AML cells. His laboratory team includes researchers like Sophie Vause and Aleksandra, who joined in late 2024.
As an educator, Dr. Simoes serves as an Academic Skills Tutor, delivers Molecular Cell Biology tutorials, and has designed advanced neuroscience workshops for postgraduate students. He supervises multiple research projects and holds Associate Fellowship of the Higher Education Academy.
His laboratory, accessible through www.simoes.science, represents a growing research group dedicated to advancing our understanding of AML biology and developing novel therapeutic approaches that target the tumor microenvironment.
